Please login to the form below

Not currently logged in
Email:
Password:

Neulasta rival from Teva cleared in EU

Lonquex offers competition to Amgen drug in neutropaenia

Teva Pharma logo

Teva Pharmaceutical has been given a green light by the European Commission (EC) for Lonquex, a rival to Amgen's blockbuster Neulasta.

Lonquex (lipegfilgrastim) has been approved to reduce the duration of neutropaenia (low white blood cell counts) and febrile neutropaenia in patients undergoing cytotoxic chemotherapy for cancer, and is given as a single subcutaneous dose per cycle of chemotherapy.

Like Neulasta (pegfilgrastim), Lonquex is a long-acting recombinant granulocyte colony-stimulating factor (G-CSF) and is dosed at the same frequency as Amgen's drug.

It will compete head-to-head with Amgen's G-CSF franchise, which also includes and short-acting variant Neupogen (filgrastim) and had combined 2012 sales of $5.4bn, with Neulasta accounting for the bulk of total. Teva already markets a biosimilar version of filgrastim in both Europe and the US.

The drug was approved as a novel medicine rather than as a biosimilar, and completed a full phase III trials programme, which showed that it was comparable to pegfilgrastim in terms of both safety and efficacy when used to shorten the duration of neutropenia after cancer chemotherapy.

"This is an important milestone for Teva Specialty Medicines in Europe and demonstrates our commitment to making a difference to the lives of those with cancer," commented Rob Koremans, chief executive of the division. Lonquex is the first biologic medicine from Teva's branded medicines division to be approved for marketing.

The EU approval has come earlier than expected, he added, at just eight weeks after the Committee for Medicinal Products for Human Use (CHMP) delivered a positive opinion on the Teva's marketing application.

Teva's biologics pipeline also includes reslizumab, a monoclonal antibody targeting interleukin-5 (IL-5) in phase III for moderate-to-severe asthma, and an albumin-fused G-CSF called balugrastim which like lipegfilgrastim is described by the company as a 'biobetter'.

Article by
Phil Taylor

9th August 2013

From: Sales

Share

Tags

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Healthcare Media Europe – HME Ltd

HME are an innovative and technology enabled agency offering our clients over 35+ years of knowledge and expertise in delivering...

Latest intelligence

Virtual Engagement At Porterhouse: Reflections on the past few months
A look at how the pitfalls of virtual engagement can be avoided and the key advantages of virtual client and KOL engagement strategies in a now predominantly digital world....
July 2020: diversity and inclusion in clinical trials round-up
COVID-19 has continued to bring diversity and health inequality to the forefront of people’s attention. Our latest round-up covers the July news around these issues, and brings you the latest...
Medical Device Clinical Trials 2020
In July 2020, we attended and exhibited at the Medical Device Clinical Trials 2020 Virtual Experience. We really enjoyed the day and it was great to hear from like-minded people,...

Infographics